294: Is CFD Overkill for Your Scale-Up? Why It Belongs in Every Biotech Scientist's Toolkit with Christian Witz - Part 2

Scale-up doesn't fail because the science was wrong. It fails because a cell's environment in a shake flask has little in common with its environment in a bioreactor. Christian Witz has spent years building the tools to close that gap: simulating exactly what a cell experiences as it moves from bench to plant, before a single liter is wasted finding out the hard way.
Continuing from Part 1, David Brühlmann and Christian Witz, CEO and founder of SimVantage, go deeper into how CFD moves from theory to daily practice: validating simulation results, scaling real cell therapy and Streptomyces processes, and an active FDA-backed project on residence time distribution in continuous bioprocessing.
Topics discussed:
• Why data validation is crucial in CFD simulations and how to interpret and trust simulation results (02:39)
• Real-world examples of scaling up from shake flasks to stirred tank reactors using CFD, including specific collaborations and cell therapy case studies (05:40)
• Technical and validation challenges in simulating fluid dynamics in shake flasks and integrating these results into scale-up strategies (08:14)
• Ongoing FDA-backed project to model residence time distribution in continuous bioprocessing and its regulatory significance (11:49)
• The increasing openness of regulators like the FDA to include CFD data in submissions and relevant guidelines for simulation credibility (13:23)
• Advice for small biotech teams on when and how to start using CFD in CMC development and scale-up planning (15:06)
• Insights on the future of bioprocessing, including virtual scale-up, digital reactor repositories, and the democratization of CFD tools (18:20)
Smart insight: Christian Witz advised that teams begin CFD modeling as early as concept development. CFD not only helps choose the right equipment—even when working with contract manufacturers—but creates a digital process record that reduces experimental burden, shortens timelines, and impresses investors with its risk mitigation.
If this conversation got you rethinking your scale-up strategy, here are a few past episodes that go deeper on the pieces Christian touched on:
• Episodes 91 - 92 : Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
• Episodes 245 - 246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei
• Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
• Episode 243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework
Connect with Christian Witz:
Website: www.simvantage.com (simvantage.com)
Christian’s LinkedIn: linkedin.com/in/christian-witz-84aa9b162
Christian’s email: christian.witz@simvantage.com
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here (smartbiotechscientist.com/#cmc)
Support the show (buzzsprout.com/2263581/support)